AMYT Amryt Pharma PLC

SVB Securities analyst Mani Foroohar reiterated a Buy rating on Amryt Pharma (AMYT - Research Report) on November 3 and set a price target of $19.00. The company's shares closed last Friday at $6.90.Foroohar covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals, Moderna, and BridgeBio Pharma. According to TipRanks, Foroohar has an average return of -15.4% and a 39.41% success rate on recommended stocks. Amryt Pharma has an analyst consensus of Strong Buy, with a price target consensus of $18.50, which is a 168.12% upside from current levels. In a report released on November 4, H.C.
https://www.tipranks.com/news/blurbs/svb-securities-keeps-their-buy-rating-on-amryt-pharma-amyt?utm_source=advfn.com&utm_medium=referral